NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

An EORTC-IATG Double-Blind Trial of Vancomycin (Van) versus Placebo (Pla) for Persistent Fever in Neutropenic Cancer Patients (NCP) given Piperacillin/tazobactam (PT) Monotherapy.

COMETTA A, KERN WV, DEBOCK R, PAESMANS M, VANDENBERGH M, CROKAERT F, ENGELHARD D, MARCHETTI O, AKAN H, BASSARIS H, KORTEN V, VISCOLI C, GLAUSER MP; THE INTERNATIONAL ANTIMICROBIAL THERAPY GROUP OF THE EORTC; Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.).

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. L-774.

CHUV, Lausanne, Switzerland

The addition of a glycopeptide in NCP with persistent fever after 48h of empirical antibiotic therapy has become a common practice. However, the benefit of this procedure has never been proved. Of a total of 763 eligible febrile NCP enrolled in a noncomparative trial of PT monotherapy (4.5g q6h), response to PT monotherapy was assessed in 598 NCP and the success rate was 52% (CI 95%: 48-56%). The enrolled NCP with unexplained fever (FUO), clinically documented infections (CDI) and PT-susceptible Gram + bacteremias (G+ Bact.) were randomized to receive Van (1g q12h) or Pla provided that they had a persistent fever and a neutropenia (<500/mm[3]) after 48-60 h of PT monotherapy. Defervescence was defined as a period of 3 complete consecutive days with a temperature < 38 degrees. Among 165 randomized eligible NCP, the median duration of neutropenia was 14 days; FUO accounted for 72% in Van and 73% in Pla, CDI for 16 and 17% and G+ Bact.for 12 and 10%, respectively. CONCLUSION: NI The present study does not support the empirical addition of Van in persistently febrile NCP not responding to initial broad-spectrum empirical antibiotic therapy. Glycopeptides can be withheld safely in such NCP and can be restricted to well defined indications in order to prevent the emergence of resistance.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Blindness
  • Body Temperature
  • Clinical Trials as Topic
  • Double-Blind Method
  • Fever
  • Fever of Unknown Origin
  • Humans
  • Infection
  • Neutropenia
  • Penicillanic Acid
  • Piperacillin
  • Placebos
  • Vancomycin
  • tazobactam
Other ID:
  • GWAIDS0029862
UI: 102269494

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov